Videos

Andrew L. Pecora, MD, FACP, CPE, discusses the biggest areas of research in the field of multiple myeloma. Pecora says that there has been a surprising number of advances in the field, with current research mostly focused on 1 of 3 areas.

Timothy F. Burns, MD, PhD, discusses the value of conducting next-generation sequencing in-house for patients with lung cancer compared with sending out to an external laboratory for molecular profiling results. Burns says he conducts NGS testing on all patients with metastatic and nonsquamous lung cancers. This includes patients that are both smokers and non-smokers.

Eric Pujade-Lauraine, MD, PhD, discusses the exploratory findings from the phase III JAVELIN Ovarian 200 trial, which investigated the use of combination avelumab plus pegylated liposomal doxorubicin in patients with platinum-resistant, refractory ovarian cancer.

Eric Harris, DO, hematologist/oncologist, Florida Cancer Specialists & Research Institute, gives Targeted Oncology an insiders perspective on the current state of community oncology in Florida and some ways the Florida Society of Clinical Oncology (FLASCO) aids in improving patient care by helping physicians.

Matthew S. Davids, MD, MMSc, discusses the significance of the findings from TRANSCEND CLL 004, a phase I/II trial investigating the CAR T-cell therapy lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia.

Recurrent Cutaneous Squamous Cell Carcinoma

Shilpa Gupta, MD, discusses the current role of immunotherapy in treating patients with bladder cancer and how biomarkers have become an unmet need.

Jae H. Park, MD, discusses the current role and challenges in using CAR T-cell therapy in patients with relapsed or refractory acute myeloid leukemia. The 2 challenges now in this area are target selection and patient selection.